フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Amsterdam, The Netherlands, and Holzgerlingen, Germany, July 01, 2020, 08:30 am CEST - Curetis N.V. in liquidatie (the "Company") today announced...
Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 30, 2020, 08:00 am CET - Curetis N.V. in liquidatie (the "Company") today announced...
Amsterdam, the Netherlands, Holzgerlingen, Germany April 20, 2020, 8:00 am CEST - Curetis N.V. in liquidatie (the "Company") announces that the...
- Following approval of shareholders, companies sign German transfer agreement - Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares...
Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transactionTransaction close anticipated...
, a developer of next-level molecular diagnostic solutions, today announced that it starts offering a CE-IVD certified real-time PCR test kit for...
Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 16:15 pm CET - Curetis N.V. (the "Company" and...
- Shareholders adopt all proposed resolutions - EGM votes clear way for closing of business combination with...
Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018More than tripled...
Exclusive distribution agreement for initial term of 3 yearsQuaphaco commits to minimum purchase totaling about EUR 1.9 million during initial...
BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCRAres...
Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 27, 2020, 08:00 am CET / 02:00 am EDT - Curetis N.V. (the...
Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 23, 2020, 10:00 am CET - Curetis N.V. (the "Company" and, together with its...
Panel also includes atypical pathogens such as Pneumocystis jiroveciiLRT BAL Panel expected to substantially increase total addressable market...
Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jiroveciiClearance expected to substantially increase total...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約